Miri Halperin Wernli

Dr Miri Halperin Wernli is a senior pharmaceutical and biomedical executive with over 25 years of strategic and operational leadership in the biopharmaceutical industry and a deep understanding of drug and product development. Dr Halperin Wernli has held worldwide senior leadership positions in product development, R&D and Strategic Marketing throughout Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals). Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Pre-clinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas. Dr. Halperin Wernli is an experienced pharmaceutical leader with skills and broad expertise in Drug Development, Regulatory Affairs, Project & Portfolio Management, Development Finance & Controlling, and Corporate Strategy and Governance.
Bio last updated 16 Jan 2017

Access to our data for Miri Halperin Wernli is only available to paid subscribers with access.

The search engine is Western Australia's most accurate and comprehensive business listings and searchable database.

Miri Halperin Wernli is linked to 1 organisation which is included in 1 list - Public Companies - Industrial.

To see the data you will need to .

Total Shareholder Return as at 31/10/18

1 year TSR5 year TSR
146thAurora Labs33%0%
501stCreso Pharma-23%0%
744 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar


Co-Founder, Chief Executive Officer
Year started and most recent title

Share Transactions

$257k Bought
Total value as at the date of the transaction
Source: Morningstar


188th-Aurora Labs$330k
189th↑Creso Pharma$244k
190th↓Wavenet International$239k
239 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer